The COVID-19 pandemic that began in Wuhan, China, has caused significant disruptions to businesses and economic activities worldwide. COVID-19 is expected to have a negative impact on the blood culture tests market due to the limited or non-availability of medical facilities/treatment centers. To reduce the strain on the healthcare system and decrease disease transmission, governments worldwide are providing guidelines to postpone or delay non-essential medical and surgical procedures. Restrictions and lockdowns were also imposed in the areas of travel, business operations, public gatherings, health clubs, and fitness/wellness centers.

The COVID-19 pandemic has affected manufacturing and construction activities worldwide. Logistic limitations and reconsiderations of the raw material requirements are becoming a problem for manufacturers. Numerous manufacturers found themselves in situations where demand greatly exceeded supply, and therefore, many laboratories struggled to continue to offer testing in some areas. This negatively affected the blood culture tests market.   

Download PDF Brochure @ 

Nosocomial (hospital-acquired) bloodstream infections are one of the leading causes of mortality across the globe. In the US alone, approximately 250,000 cases of hospital-acquired BSIs occur each year. Globally, bloodstream infections affect about 30 million people leading to 6 million deaths, with 3 million newborns and 1.2 million children suffering from sepsis annually. 

In Eastern African countries, the proportion of patients with bloodstream infections is reported to range from 11% to 28%. In Ghana, bloodstream infection rates are estimated to be in the range of 9.3% to 11.2% (Source: Journal of Tropical Medicine, 2019). The occurrence of these infections increases the overall duration of hospitalization as well as the cost of treatment. With the high incidence of BSIs, the demand for advanced blood culture techniques that help in the early detection of infections is expected to increase. 

[190 Pages Report] The market for blood culture tests is expected to grow from USD 4.0 billion in 2020 to USD 6.1 billion by 2025, at a CAGR of 8.9% during the forecast period. Growth in the blood culture tests market is attributed to factors such as increasing number of sepsis cases and high cost of treatment, rising geriatric population, high incidence of bloodstream infections, growth in the demand for rapid diagnostic techniques, and the high prevalence of infectious diseases. 

In recent years, several technologically advanced products that provide enhanced solutions for the detection of microorganisms present in the bloodstream have been launched in the market. These advanced products are expected to cannibalize the market for conventional products, such as microscopes and polystainers, thereby affecting the growth of conventional blood culture testing products. 

The high growth in these markets can primarily be attributed to the growth in the prevalence of infectious diseases, rapid growth in the geriatric population, the growing number of product approvals, and rising healthcare expenditure. For instance, the healthcare expenditure in China increased to 5.35% of the GDP in 2018 from USD 4.88% of GDP in 2015 (Source: World Bank, OECD).  

On the basis of d applications, the blood culture tests market is segmented into bacteremia, fungemia, and mycobacterial detection. Among these application segments, bacteremia accounted for the largest market share of in 2019. This segment is also expected to grow at the highest CAGR during the forecast period.